The company's lead product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor. Cascadian Therapeutics is also developing Checkpoint kinase 1, a protein kinase that regulates the cell division cycle and DNA damage. Additionally, the company focuses on developing novel antibodies and T-cell immunoreceptor with Ig and ITM domains to negatively regulate immune response to cancers. Cascadian Therapeutics has license and collaboration agreements with Array BioPharma, Sentinel Oncology, and Adimab for the development of its products.